121 related articles for article (PubMed ID: 26254394)
21. Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Wong ET; Timmons J; Callahan A; O'Loughlin L; Giarusso B; Alsop DC
BMC Cancer; 2016 Nov; 16(1):914. PubMed ID: 27876012
[TBL] [Abstract][Full Text] [Related]
22. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Kyritsis AP; Levin VA
Cancer Chemother Pharmacol; 2011 May; 67(5):971-83. PubMed ID: 21442438
[TBL] [Abstract][Full Text] [Related]
23. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
25. First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
Seiz M; Kohlhof P; Brockmann MA; Neumaier-Probst E; Hermes P; VON Deimling A; Vajkoczy P; Schmieder K; Tuettenberg J
Anticancer Res; 2009 Aug; 29(8):3261-7. PubMed ID: 19661344
[TBL] [Abstract][Full Text] [Related]
26. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Hau P; Kunz-Schughart L; Bogdahn U; Baumgart U; Hirschmann B; Weimann E; Muhleisen H; Ruemmele P; Steinbrecher A; Reichle A
Oncology; 2007; 73(1-2):21-5. PubMed ID: 18332649
[TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Zustovich F; Lombardi G; Della Puppa A; Rotilio A; Scienza R; Pastorelli D
Anticancer Res; 2009 Oct; 29(10):4275-9. PubMed ID: 19846986
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
30. Angiogenesis in malignant glioma--a target for antitumor therapy?
Tuettenberg J; Friedel C; Vajkoczy P
Crit Rev Oncol Hematol; 2006 Sep; 59(3):181-93. PubMed ID: 16860996
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
32. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Nanegrungsunk D; Onchan W; Chattipakorn N; Chattipakorn SC
Neurol Res; 2015 Feb; 37(2):167-83. PubMed ID: 25033940
[TBL] [Abstract][Full Text] [Related]
33. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
35. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Taal W; Brandsma D; de Bruin HG; Bromberg JE; Swaak-Kragten AT; Smitt PA; van Es CA; van den Bent MJ
Cancer; 2008 Jul; 113(2):405-10. PubMed ID: 18484594
[TBL] [Abstract][Full Text] [Related]
36. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
37. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
39. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
Wong ML; Prawira A; Kaye AH; Hovens CM
J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
